FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission granted a marketing authorisation valid throughout the EU for Viraferon to SP Europe on 9 March 2000.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Viraferon, veljavno po vsej Evropski uniji, odobrila družbi SP Europe dne 9. marca 2000.
English: Because Viraferon can be associated with side effects such as depression, patients must be closely monitored during treatment.
Slovenian: Ker je mogoče zdravilo Viraferon povezati z neželenimi učinki, kot je depresija, je treba bolnike med zdravljenjem pozorno spremljati.
English: Alpha interferons may also block the multiplication of viruses.
Slovenian: Interferoni alfa utegnejo tudi blokirati razmnoževanje virusov.
English: • children and adolescents with a history of severe mental illness, particularly severe depression,
Slovenian: • otrocih in mladostnikih z anamnezo hude duševne bolezni, še posebej hude depresije,
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) VIRAFERON EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) VIRAFERON Povzetek EPAR za javnost
English: In children it is used with ribavirin.
Slovenian: Pri otrocih se uporablja v kombinaciji z ribavirinom.
English: Treatment with Viraferon should be initiated by a doctor who has experience in the management of the disease it is being used for.
Slovenian: Zdravljenje z zdravilom Viraferon mora uvesti zdravnik, ki ima izkušnje z zdravljenjem bolezni, za katero se uporablja.
English: Viraferon should not be used in:
Slovenian: Zdravila Viraferon se ne sme uporabljati pri:
English: It is available as a powder and solvent to be made up into a solution for injection or infusion, as a ready-to-use solution for injection and as a multidose pen for injection.
Slovenian: Na voljo je kot prašek in vehikel za pripravo raztopine za injiciranje ali infundiranje, kot predhodno pripravljena raztopina za injiciranje ter kot večodmerni peresnik za injiciranje.
English: Other information about Viraferon:
Slovenian: Druge informacije o zdravilu Viraferon:
English: Because interferon alfa-2b has been used to treat a number of diseases in the European Union (EU) before, the company that makes Viraferon supplied data from the scientific literature and from studies of its use in children with chronic hepatitis B. The company also supplied information from a number of studies of Viraferon used alone or with ribavirin for the treatment of chronic hepatitis C. These included a total of 2,552 treatment-naïve patients (who had not been treated before) and a total of 345 patients whose disease had relapsed (returned) after previous treatment with interferon.
Slovenian: Ker se je interferon alfa-2b že prej uporabljal za zdravljenje številnih bolezni v Evropski uniji (EU), je podjetje, ki izdeluje zdravilo Viraferon, predložilo podatke iz znanstvene literature in študij o njegovi uporabi pri otrocih s kroničnim hepatitisom B. Podjetje je predložilo tudi podatke iz številnih študij zdravila Viraferon, uporabljenega samostojno ali v kombinaciji z ribavirinom pri zdravljenju kroničnega hepatitisa C. V teh študijah je sodelovalo skupno 2552 predhodno nezdravljenih bolnikov (ki dotlej še niso prejemali zdravil) in skupno 345 bolnikov, pri katerih se je bolezen ponovila po predhodnem zdravljenju z interferonom.
English: • patients with thyroid disease unless it is controlled,
Slovenian: • bolnikih z boleznijo ščitnice, razen če je obvladana,
English: • patients with epilepsy or other central nervous system problems,
Slovenian: • bolnikih z epilepsijo ali drugimi motnjami delovanja centralnega živčnega sistema,
English: The studies showed that Viraferon is effective in the diseases for which it can be used.
Slovenian: Študije so pokazale, da je zdravilo Viraferon učinkovito pri zdravljenju bolezni, za katere je namenjeno.
English: It was also effective in children when used with ribavirin, with 46% of the children having responded to treatment at the six-month follow up visit following a year's treatment.
Slovenian: V kombinaciji z ribavirinom je bilo učinkovito tudi pri otrocih, saj je bilo ob pregledu po šestmesečnem obdobju spremljanja, ki je sledilo enoletnemu zdravljenju, ugotovljeno, da se je na zdravljenje odzvalo 46 % otrok.
English: • patients with severe kidney or liver disease including that caused by cancer,
Slovenian: • bolnikih s hudo boleznijo ledvic ali jeter, vključno s takšno, ki jo povzroča rak,
English: The use of Viraferon in combination with ribavirin has also been studied in 118 hepatitis C treatment-naïve children aged between three and 16 years.
Slovenian: Uporabo zdravila Viraferon v kombinaciji z ribavirinom so preučevali tudi pri 118 predhodno nezdravljenih otrocih s hepatitisom C, starimi med tri in 16 let.
English: Viraferon can be used on its own but is best used in combination with ribavirin (an antiviral medicine).
Slovenian: Pri odraslih je zdravilo Viraferon mogoče uporabljati samostojno, vendar je bolje, če se uporablja v kombinaciji z ribavirinom (protivirusnim zdravilom).
English: The interferon alfa-2b in Viraferon is produced by a method known as ‘recombinant DNA technology': the interferon alfa-2b is made by a bacterium that has received a gene (DNA), which makes it able to produce it.
Slovenian: Interferon alfa-2b, ki ga vsebuje zdravilo Viraferon, se proizvaja po metodi, imenovani „rekombinantna DNA tehnologija“: proizvaja ga bakterija, ki je prejela gen (DNA), kar ji omogoča njegovo tvorjenje.
English: For more information, see the Package Leaflet.
Slovenian: Za več informacij glejte Navodilo za uporabo.
English: • hepatitis patients who have liver cirrhosis (scarring) that is causing symptoms or who have recently received medicines that affect the immune system,
Slovenian: • bolnikih s hepatitisom, ki imajo cirozo jeter, ki povzroča simptome, ali ki so nedavno prejemali zdravila, ki vplivajo na imunski sistem,
English: What is the risk associated with Viraferon?
Slovenian: Kakšna tveganja so povezana z zdravilom Viraferon?
English: What benefit has Viraferon shown during the studies?
Slovenian: Kakšne koristi je zdravilo Viraferon izkazalo med raziskavami?
English: The replacement interferon alfa-2b acts in same way as naturally produced interferon alpha.
Slovenian: Nadomestni interferon alfa-2b deluje na enak način kot naravno proizvedeni interferon alfa.
English: • chronic hepatitis C (a disease of the liver due to an infection by the hepatitis C virus).
Slovenian: • kroničnega hepatitisa C (bolezni jeter, ki je posledica okužbe z virusom hepatitisa C).
English: Similar side effects have been seen in children receiving Viraferon, as well as inhibition of growth.
Slovenian: Podobni neželeni učinki so bili opaženi pri otrocih, ki so prejemali zdravilo Viraferon, kakor tudi zavirana rast.
English: Viraferon should not be used in people who may be hypersensitive (allergic) to interferon alfa-2b or any of the other ingredients.
Slovenian: Zdravilo Viraferon se ne sme uporabljati pri ljudeh, ki utegnejo biti preobčutljivi za (alergični na) interferon alfa-2b ali katero koli drugo sestavino.
English: • patients with a history of certain disorders of the immune system, or who have had an organ transplant and are taking medicines that suppress the immune system,
Slovenian: • bolnikih, ki imajo določene motnje imunskega sistema v anamnezi ali so imeli presaditev organa in jemljejo zdravilo za zaviranje delovanja imunskega sistema,
English: Viraferon is used for the treatment of:
Slovenian: Zdravilo Viraferon se uporablja za zdravljenje:
English: • patients with a history of severe heart disease,
Slovenian: • bolnikih z anamnezo hudega obolenja srca,
English: Viraferon is a medicine containing the active substance interferon alfa-2b.
Slovenian: Viraferon je zdravilo, ki vsebuje zdravilno učinkovino interferon alfa-2b.
English: For the full list of all side effects reported with Viraferon, see the Package Leaflet.
Slovenian: Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Viraferon, glejte Navodilo za uporabo.
English: Viraferon was also shown to have a benefit in children with chronic hepatitis B. Viraferon, with or without ribavirin, was shown to be effective in treating hepatitis C in both treatment-naïve and relapsed adults.
Slovenian: Zdravilo Viraferon je izkazalo koristi tudi pri otrocih s kroničnim hepatitisom B. Zdravilo Viraferon v kombinaciji z ribavirinom ali brez njega je bilo učinkovito pri zdravljenju hepatitisa C pri predhodno nezdravljenih odraslih in odraslih s ponovitvijo bolezni.
English: • chronic (long-term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus)
Slovenian: • kroničnega (dolgotrajnega) hepatitisa B (bolezni jeter, ki je posledica okužbe z virusom hepatitisa B) pri odraslih;
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Viraferon's benefits are greater than its risks for the treatment of chronic hepatitis B and C. The Committee recommended that Viraferon be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Viraferon pri zdravljenju kroničnega hepatitisa B in C večje od z njim povezanih tveganj.
English: The full EPAR for Viraferon is available here.
Slovenian: Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Viraferon je na voljo tukaj.
English: Why has Viraferon been approved?
Slovenian: Zakaj je bilo zdravilo Viraferon odobreno?
English: The active substance in Viraferon, interferon alfa-2b, belongs to the group ‘interferons'.
Slovenian: Zdravilna učinkovina zdravila Viraferon, interferon alfa-2b, spada v skupino interferonov.
English: For a list of all restrictions with Viraferon, see the Package Leaflet.
Slovenian: Za celoten seznam omejitev za zdravilo Viraferon glejte Navodilo za uporabo.
English: How has Viraferon been studied?
Slovenian: Kako je bilo zdravilo Viraferon raziskano?
English: What is Viraferon used for?
Slovenian: Za kaj se zdravilo Viraferon uporablja?
English: What is Viraferon?
Slovenian: Kaj je zdravilo Viraferon?
English: How is Viraferon used?
Slovenian: Kako se zdravilo Viraferon uporablja?
English: How does Viraferon work?
Slovenian: Kako zdravilo Viraferon deluje?
English: • Not drink Grapefruit Juice
Slovenian: • ne sme piti soka grenivke;
English: The PAC must include the following key messages:
Slovenian: Kartica OKB mora vsebovati naslednja ključna sporočila:
English: • Have ever had an abnormal electrocardiogram (ECG)
Slovenian: • je kadar koli imel nenormalen elektrokardiogram (EKG);
English: • Is taking allergy medicines
Slovenian: • jemlje zdravila proti alergiji.
English: • Is taking medications to treat epilepsy, bacterial or fungal infections, HIV infection, depression or heart rhythm disorders
Slovenian: • jemlje zdravila proti epilepsiji, bakterijskim ali glivičnim okužbam, okužbi z virusom HIV, depresiji ali motnjam srčnega ritma;
English: • A dose reduction of Ranexa may be needed in combination with:
Slovenian: • Zmanjšanje odmerka zdravila Ranexa bo morda potrebno v kombinaciji z:
English: • Call their doctor if they feel dizzy or sick, become sick or experience any unexpected symptoms after starting Ranexa.
Slovenian: • mora poklicati zdravnika, če je omotičen ali če mu je slabo, če bruha ali če ima kakršne koli nepričakovane simptome po začetku jemanja zdravila Ranexa.
English: • That the card should be shown to any doctor involved in their treatment
Slovenian: • Bolnik mora kartico pokazati vsakemu zdravniku, ki sodeluje v njegovem zdravljenju.
English: • Inform the patient about the potential for an interaction with other prescribed medicinal products and to contact his/her doctor in case of dizziness, nausea or vomiting.
Slovenian: • Bolnika je treba obvestiti o možnosti interakcij z drugimi predpisanimi zdravili in mu naročiti, naj obvesti svojega zdravnika, če se pojavijo omotica, navzeja ali bruhanje.
English: • With certain other risk factors listed in the product information
Slovenian: • z nekaterimi drugimi dejavniki tveganja, navedenimi v informacijah o zdravilu.
English: • Taking certain other drugs mentioned in the product information
Slovenian: • ki jemljejo nekatera druga zdravila, omenjena v informacijah o zdravilu;
English: • Ranexa is contraindicated in patients taking:
Slovenian: • Zdravilo Ranexa je kontraindicirano pri bolnikih, ki jemljejo:
English: • Caution should be exercised when prescribing Ranexa to patients:
Slovenian: • Previdnost je potrebna pri predpisovanju zdravila Ranexa bolnikom:
English: • Liver problems
Slovenian: • ima težave z jetri;
English: ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Slovenian: DODATEK IV POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO IZVAJATI DRŽAVE ČLANICE
English: Patient information The PAC should include the following information for the patient:
Slovenian: Informacije za bolnika Kartica OKB mora vsebovati naslednje informacije za bolnika:
English: The Pharmacist should be requested to distribute a PAC to each patient at the time Ranexa is dispensed.
Slovenian: Od farmacevta je treba zahtevati, da kartico OKB da vsakemu bolniku, kadar izda zdravilo Ranexa.
English: • Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than Amiodarone
Slovenian: • antiaritmike razreda Ia (npr. kinidin) ali razreda III (npr. dofetilid, sotalol), razen amiodarona.
English: • Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone)
Slovenian: • močne zaviralce CYP3A4 (npr. itrakonazol, ketokonazol, vorikonazol, posakonazol, zaviralce proteaze virusa HIV, klaritromicin, telitromicin, nefazodon);
English: Health Care Professional information The PAC should include the following information for the healthcare professional information regarding Ranexa:
Slovenian: Informacije za zdravnike Kartica OKB mora vsebovati naslednje informacije za zdravnike o zdravilu Ranexa:
English: • Moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole)
Slovenian: • zmernimi zaviralci CYP3A4 (npr. diltiazemom, eritromicinom, flukonazolom);
English: • To refer to the Ranexa SPC prior to prescribing any medications to the patient, as there are potential drug interactions which should be taken into consideration.
Slovenian: • Navodilo, naj pred predpisovanjem katerega koli zdravila bolniku preberejo povzetek glavnih značilnosti zdravila, saj obstajajo morebitne interakcije z drugimi zdravili, ki jih je treba upoštevati.
English: • That prior to Ranexa treatment the patient should tell their doctor if they have any of the following:
Slovenian: • Pred zdravljenjem z zdravilom Ranexa mora bolnik obvestiti zdravnika, če:
English: The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: The Member States shall agree the details of a Patient Alert Card (PAC) with the MAH, who must provide this PAC directly to the pharmacy with each Ranexa shipment.
Slovenian: Država članica se mora o podrobnostih na Opozorilni kartici za bolnika (OKB) dogovoriti z imetnikom dovoljenja za promet z zdravilom, ki mora kartico OKB poslati neposredno lekarnam ob vsaki pošiljki zdravila Ranexa.
English: • P-gp inhibitors (e.g. ciclosporin, verapamil)
Slovenian: • zaviralci P-gp (npr. ciklosporinom, verapamilom)
English: • Kidney problems
Slovenian: • ima težave z ledvicami;
English: • That during treatment with Ranexa the patient should:
Slovenian: • Med zdravljenjem z zdravilom Ranexa bolnik:
English: • To ensure to take a list of all their other medicines with them at any visit to the health care professional.
Slovenian: • Ob vsakem obisku zdravnika mora bolnik s sabo vzeti seznam vseh drugih zdravil, ki jih jemlje.
English: • To refer to the Ranexa package leaflet for more information.
Slovenian: • Bolnik lahko več informacij najde v navodilu za uporabo zdravila Ranexa.
English: • Is taking the herbal remedy St John's Wort
Slovenian: • jemlje zeliščni pripravek, ki vsebuje šentjanževko;
English: 50 ml (16 mg/ml) 1 vial
Slovenian: 50 ml (16 mg/ml) 1 viala
English: 800 mg Concentrate for solution for infusion
Slovenian: 800 mg Koncentrat za raztopino za infundiranje
English: Intravenous use Vial (glass)
Slovenian: Viala (steklena)
English: The capsules must never be swallowed.
Slovenian: Kapsule se ne smejo nikoli pogoltniti.
English: The evening dose should be taken two to three hours before bedtime.
Slovenian: Večerni odmerek se vzame dve do tri ure pred spanjem.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Bronchitol on 13 April 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Bronchitol, veljavno po vsej Evropski uniji, odobrila dne 13. aprila 2012.
English: This means that it can promote osmosis (the flow of liquid across a membrane).
Slovenian: To pomeni, da lahko spodbuja osmozo (pretok tekočine skozi membrano).
English: This is a summary of the European public assessment report (EPAR) for Bronchitol.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Bronchitol.
English: Some patients also received additional treatment with rhDNase (another treatment for cystic fibrosis).
Slovenian: Nekateri bolniki so prejeli tudi dodatno zdravljenje z rhDNAzo (drugo zdravilo za cistično fibrozo).
English: FEV1 is the maximum volume of air a person can breathe out in one second.
Slovenian: FEV1 je največji volumen zraka, ki ga bolnik lahko izdihne v eni sekundi.
English: In order to obtain further information on effectiveness and safety of Bronchitol in children and adolescents with cystic fibrosis the CHMP requested the company to carry out a study in this patient group.
Slovenian: Za pridobitev dodatnih informacij o učinkovitosti in varnosti uporabe zdravila Bronchitol pri otrocih in mladostnikih s cistično fibrozo je odbor CHMP zahteval, da družba opravi študijo s to skupino bolnikov.
English: Other information about Bronchitol
Slovenian: Druge informacije o zdravilu Bronchitol
English: For more information about treatment with Bronchitol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Bronchitol preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The effects of Bronchitol were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Bronchitol so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: The recommended dose is 400 mg (which requires the inhalation of the content of 10 capsules loaded individually into the inhaler) twice a day in the morning and in the evening.
Slovenian: Priporočeni odmerek je 400 mg (kar pomeni vdihavanje vsebine 10 kapsul; vsebino vsake kapsule posebej je treba prenesti v inhalator) dvakrat dnevno, zjutraj in zvečer.
English: The company that makes Bronchitol must ensure that all healthcare professionals expected to prescribe the medicine are provided with important safety information including information on the risk of narrowing of the airways in the lungs and the coughing of blood and how to manage this risk.
Slovenian: Družba, ki izdeluje zdravilo Bronchitol, mora zagotoviti, da so vsi zdravniki, za katere se pričakuje, da bodo zdravilo predpisovali, seznanjeni s pomembnimi informacijami o varnosti, vključno z informacijami o tveganju za zožitev dihalnih poti v pljučih in izkašljevanje krvi ter o načinih obvladovanja teh tveganj.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Bronchitol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Slovenian: Povzetek mnenja Odbora za zdravila sirote za zdravilo Bronchitol je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
English: It is available as capsules (40 mg) containing a dry powder for inhalation using an inhaler device.
Slovenian: Na voljo je v obliki kapsul (40 mg), ki vsebujejo suh prašek za vdihavanje z inhalatorjem.
English: Bronchitol was tested in two main studies involving 642 patients between six and 56 years of age with mild or moderate cystic fibrosis.
Slovenian: Bronchitol so preskusili v dveh glavnih študijah, ki sta vključevali 642 bolnikov, starih od 6 do 56 let, z blago ali zmerno cistično fibrozo.
English: What measures are being taken to ensure the safe use of Bronchitol?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Bronchitol?
English: In both studies the patients received either 400 mg of inhaled Bronchitol twice daily or 50 mg of inhaled Bronchitol twice daily (which was considered ineffective and hence intended as placebo (dummy treatment)).
Slovenian: V obeh študijah so bolniki prejemali bodisi 400 mg vdihanega zdravila Bronchitol dvakrat dnevno bodisi 50 mg vdihanega zdravila Bronchitol dvakrat dnevno (kar naj bi bilo neučinkovito in zato mišljeno kot uporaba placeba (zdravilo brez zdravilne učinkovine)).
English: EPAR summary for the public
Slovenian: Povzetek EPAR za javnost manitol
English: The most common side effect with Bronchitol (seen in more than 1 patient in 10) is cough.
Slovenian: Najpogostejši neželeni učinek zdravila Bronchitol (opažen pri več kot 1 bolnikih od 10) je kašelj.
English: Regarding the safety of Bronchitol, the CHMP considered that sufficient measures have been proposed by the company to reduce the risks of bronchospasm and haemoptysis.
Slovenian: Kar zadeva varnost zdravila Bronchitol, je Odbor menil, da je družba predlagala zadostne ukrepe za zmanjšanje tveganja za pojav bronhospazma in hemoptize.
English: This first dose of 400 mg Bronchitol should only be given under the supervision of a qualified healthcare professional in a setting where the patient's breathing can be properly monitored and facilities for resuscitation are available.
Slovenian: Ta prvi, 400-miligramski, odmerek zdravila Bronchitol se lahko daje samo pod nadzorom usposobljenega zdravstvenega delavca v okoliščinah, v katerih je mogoče ustrezno spremljati bolnikovo dihanje in kjer je na voljo oprema za oživljanje.
English: Because the number of patients with cystic fibrosis is low, the disease is considered ‘rare', and Bronchitol was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November
Slovenian: Ker je število bolnikov s cistično fibrozo malo, velja ta bolezen za redko, zato je bilo zdravilo Bronchitol dne 7. novembra 2005 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: The exact way in which Bronchitol works in cystic fibrosis is not known.
Slovenian: Natančen način delovanja zdravila Bronchitol pri cistični fibrozi še ni razjasnjen.
English: The full EPAR for Bronchitol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Bronchitol je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What benefit has Bronchitol shown during the studies?
Slovenian: Kakšne koristi je zdravilo Bronchitol izkazalo med študijami?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bronchitol.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Bronchitol, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Bronchitol is used for the treatment of cystic fibrosis in adults in addition to best standard of care.
Slovenian: Zdravilo Bronchitol se uporablja za zdravljenje cistične fibroze pri odraslih v kombinaciji z najboljšim standardom oskrbe.